Search Results
May 12, 2026, 08:30 ET Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
(TSXV: VPT) (OTCPK: VPTDF), BridgeBio Pharma (NASDAQ: BBIO), Bristol Myers Squibb (NYSE: BMY), Arrowhead Pharmaceuticals (NASDAQ: ARWR), and Amgen (NASDAQ: AMGN).
More news about: USA News Group
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
disease that targets the $65 billion metabolic syndrome opportunity through hormonal regulation of fat metabolism. Arrowhead Pharmaceuticals (NASDAQ: ARWR) dosed the first patients in a Phase 1/2a trial of ARO-DIMER-PA, the first clinical candidate designed to silence two genes simultaneously for atherosclerotic
More news about: Equity Insider
Feb 04, 2026, 18:15 ET Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Corp. (NYSE: CIEN) will replace Dayforce Inc. (NYSE: DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE: ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective
More news about: S&P Dow Jones Indices
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
(NASDAQ: MNKD), Altimmune (NASDAQ: ALT), Lineage Cell Therapeutics (NYSE-A: LCTX), and Arrowhead Pharmaceuticals (NASDAQ: ARWR).
More news about: USA News Group